SCHEMBL8509367

SCHEMBL8509367

CC(C)(C)OC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)O[C@H]1CN2CCC1CC2

nearest known ligand 0.63

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KLK7 P49862 1/20 0.63
TACR1 P25103 2/20 0.61
CTSL P07711 2/20 0.56
CTSS P25774 1/20 0.56
CTSK P43235 1/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
MAPT P10636 2/20 0.54
TP53 P04637 1/20 0.54
CCKAR P32238 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.53
CCKBR P32239 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8509371 1.00 KLK7 (0.63) KLK7TACR1CTSLCTSSCTSK
SCHEMBL2485597 0.84 CHRM3 (0.52) KLK7CTSLCTSSCTSKKMT2A
SCHEMBL2996529 0.84 CHRM3 (0.52) KLK7CTSLCTSSCTSKKMT2A
SCHEMBL2485594 0.84 CHRM3 (0.52) KLK7CTSLCTSSCTSKKMT2A
SCHEMBL8509946 0.82 KLK7 (0.58) KLK7TACR1CTSLCTSSCTSK
Bromide SCHEMBL8513155 0.81 KLK7 (0.57) KLK7TACR1CTSLCTSSCTSK
SCHEMBL5251038 0.81 TACR1 (0.78) KLK7TACR1CTSLCTSSCTSK
SCHEMBL1486155 0.81 TACR1 (0.78) KLK7TACR1CTSLCTSSCTSK
SCHEMBL621684 0.81 TACR1 (0.78) KLK7TACR1CTSLCTSSCTSK
SCHEMBL29400174 0.81 TACR1 (0.78) KLK7TACR1CTSLCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2643295-B1 GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS CHIESI FARMA SPA (IT) 2016-04-13 EP disclosed
EP-2643295-B1 GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS CHIESI FARMA SPA (IT) 2016-04-13 EP disclosed
US-8772314-B2 Glycine derivatives and medicinal compositions thereof CHIESI FARMACEUTICI S.P.A. (IT) 2014-07-08 US disclosed
US-8772314-B2 Glycine derivatives and medicinal compositions thereof CHIESI FARMACEUTICI S.P.A. (IT) 2014-07-08 US disclosed
US-8772314-B2 Glycine derivatives and medicinal compositions thereof CHIESI FARMACEUTICI S.P.A. (IT) 2014-07-08 US disclosed
EP-2643295-A1 GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS Chiesi Farmaceutici S.p.A. (IT) 2013-10-02 EP disclosed
US-20120134934-A1 GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF CHIESI FARMACEUTICI S.P.A. (IT) 2012-05-31 US disclosed
US-20120134934-A1 GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF CHIESI FARMACEUTICI S.P.A. (IT) 2012-05-31 US disclosed
WO-2012069275-A1 GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS CHIESI FARMACEUTICI S.P.A. (IT) 2012-05-31 WO disclosed
US-20120134934-A1 GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF CHIESI FARMACEUTICI S.P.A. (IT) 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120134934-A1 GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF CHRM3, GLRB, CHRNG KLK7 2641/4885TACR1 115/4885CTSL 3619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.